Handelsavisen
prelaunch
Companies Healthcare SYG.WA
SY
SYG.WA Warsaw Stock Exchange Biotechnology & Medical Research

Syg.Wa

$1,47
Open in Charts → Attach watcher ⌖
PLN
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
37,1M PLN
P/E
EV / Rev
Div yield
Op margin
37,0 %
ROE
8,0 %
Net margin
26,1 %
Debt / equity
0,14
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

SYG.WA operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Business. SYG.WA operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
8,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SYG.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SYG.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SYG.WA operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    SYG.WA has a market capitalization of $15.15 million and a price-to-earnings ratio of 5.92, indicating a relatively low valuation compared to its earnings. The company's price-to-book ratio is 0.48, suggesting that the market values the company at a discount to its book value. The enterprise value to EBITDA ratio is 5.44, and the enterprise value to revenue ratio is 2.01, both of which are metrics used to assess the company's valuation relative to its earnings and revenue.

    In terms of profitability, SYG.WA has a return on equity of 8.04% and a return on assets of 4.45%, which are measures of how effectively the company is using its equity and assets to generate profits. The company's operating income is $3.63 million, and its net income is $2.56 million, indicating a healthy margin after operating expenses and taxes. The debt-to-equity ratio is 0.14, suggesting that the company is not heavily leveraged and has a relatively low financial risk.

    SYG.WA's revenue is concentrated in a single segment, as no specific segments are disclosed in the financial data. The company's geographic exposure is not detailed in the provided data, but the lack of segment or geographic breakdown suggests that it may not have significant international operations.

    The company's growth trajectory is not explicitly detailed in the provided data, but the current liquidity risk is assessed as medium, and the dilution risk is low. The company's operating cash flow is negative at -$363,360, which could indicate short-term liquidity challenges, but its free cash flow is positive at $4.56 million, suggesting that the company is generating sufficient cash to support its operations and potentially fund growth.

    The risk assessment for SYG.WA includes a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could affect its ability to meet short-term obligations. The company's capital structure is relatively conservative, with a current ratio of 1.15, indicating that it has enough current assets to cover its current liabilities.

    Recent events and filings for SYG.WA are not detailed in the provided data, but the company's financial health and risk profile suggest that it is in a stable position with moderate financial leverage and a positive free cash flow.

    Key takeaways
    • SYG.WA has a low price-to-earnings ratio of 5.92, indicating a relatively undervalued stock.
    • The company's return on equity of 8.04% and return on assets of 4.45% suggest efficient use of equity and assets to generate profits.
    • SYG.WA's debt-to-equity ratio of 0.14 indicates a conservative capital structure with low financial risk.
    • The company's free cash flow of $4.56 million suggests it has the financial flexibility to support operations and potential growth.
    • The company's liquidity risk is assessed as medium, and its dilution risk is low.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,47
    Market cap
    $15.1M
    Enterprise value
    $19.7M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.5x
    P / Tangible book
    0.5x
    Tangible book
    $31.8M
    Net cash
    -$4.6M
    Current ratio
    1.1
    Debt / equity
    0.1
    ROA
    4.5%
    ROE
    8.0%
    Cash conversion
    -14.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin37,0 %Above P75
    Net Margin26,1 %Above P75
    ROE8,0 %Above P75
    D/E0,14Below median
    Cash Conv-0,14Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • SYG.WA Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SYG.WACanonical
    Warsaw Stock Exchange · PLN

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage